Striving for equity: Patient prioritization during a critical cancer drug shortage
Pediatr Blood Cancer
.
2021 Nov;68(11):e29280.
doi: 10.1002/pbc.29280.
Epub 2021 Aug 6.
Authors
Brittany M Lee
1
2
3
,
Nancy S Jecker
4
5
,
Jonathan M Marron
6
7
,
Abby R Rosenberg
2
3
Affiliations
1
Treuman Katz Center for Pediatric Bioethics, Seattle Children's Hospital and Research Institute, Seattle, Washington, USA.
2
Department of Pediatrics, Division of Hematology/Oncology, University of Washington School of Medicine, Seattle, Washington, USA.
3
Palliative Care and Resilience Lab, Seattle Children's Research Institute, Seattle, Washington, USA.
4
Department of Bioethics and Humanities, University of Washington School of Medicine, Seattle, Washington, USA.
5
Fulbright U.S. Scholar Program, University of Johannesburg, Johannesburg, Gauteng, South Africa.
6
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
7
Center for Bioethics, Harvard Medical School, Boston, Massachusetts, USA.
PMID:
34357696
DOI:
10.1002/pbc.29280
No abstract available
Publication types
Research Support, N.I.H., Extramural
MeSH terms
Antineoplastic Agents* / supply & distribution
Health Care Rationing*
Humans
Neoplasms* / drug therapy
Substances
Antineoplastic Agents
Grants and funding
R01 CA222486/CA/NCI NIH HHS/United States
R01 CA225629/CA/NCI NIH HHS/United States